Litcius/Paper detail

Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis

Katie A Parsels, Robert W. Seabury, Stephanie Zyck, Christopher D. Miller, Satish Krishnamurthy, William Darko, Luke A. Probst, Julius Gene Latorre, Gregory M. Cwikla, Elizabeth A. Feldman

2022The American Journal of Emergency Medicine32 citationsDOI

Topics & Concepts

MedicineRivaroxabanApixabanHemostasisRetrospective cohort studyProthrombin complex concentrateSingle CenterCohortIntracerebral hemorrhageInternal medicineAnesthesiaSurgeryWarfarinSubarachnoid hemorrhageAtrial fibrillationIntracerebral and Subarachnoid Hemorrhage ResearchAtrial Fibrillation Management and OutcomesTrauma, Hemostasis, Coagulopathy, Resuscitation
Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis | Litcius